Replies to post #18614 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

I guess LEO is just being a good sport and letting GTCB use their name in these repeated lies.

LMAO—perhaps this is the for cause violation that Leo is asserting in the pending litigation.

You also claimed that LEO has determined that rATIII doesn't work in DIC…

You really do have a problem with English, Vinny—I can now see why you’ve called so many posters on this board a liar at one time or another.

For the record, my opinion is that Leo didn’t think ATryn worked well enough in DIC to justify continuing the clinical program. I find this explanation is about 1,000 more plausible than the “portfolio reprioritization” excuse that GTC put forth.